 Oyster Point Pharma Inc NASDAQ: OYST has announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 varenicline and OC-02 simpinicline nasal sprays for dry eye disease in Greater China. Under the agreement terms, Oyster Point will receive an upfront payment consisting of 17.5 million in cash and up to 0.75 of shares in Ji Xing, half of which is subject to a pre-specified vesting condition. 